News Article

BOSS Medical Signs Exclusive License Agreement with The Johns Hopkins University
Date: Jun 26, 2013
Source: Company Data ( click here to go to the source)

Featured firm in this article: Avitus Orthopaedics Inc of Shelton, CT

Baltimore, MD (June 26, 2013) — BOSS Medical, Inc., a Maryland-based start-up medical device company, has announced the signing of an exclusive license agreement with Johns Hopkins University to develop and commercialize a novel orthopaedic surgical device for autologous bone graft harvesting. The technology was developed by biomedical engineers at the Johns Hopkins University Center for Bioengineering Innovation and Design as well as surgeons at the Department of Orthopaedic Surgery at the Johns Hopkins University School of Medicine.

"This license agreement with Johns Hopkins University is a crucial milestone for the Company that will propel our fundraising and commercialization efforts," said Maxim Budyansky, MSE, Chief Technology Officer and co-founder of BOSS Medical, Inc. as well as co-inventor of the technology. "The bone harvesting technology underlying this agreement is poised to deliver value to key healthcare stakeholders. The novel device aims to provide surgeons with an intuitive way to harvest gold standard autologous bone graft in a streamlined and minimally invasive manner for the benefit of their patients. The technology will also provide economic value to hospitals and payors, an important factor in today's cost-constrained healthcare environment."

About BOSS Medical, Inc. - BOSS Medical, Inc. was established with the mission of developing new orthopaedic technologies that improve clinical outcomes while decreasing healthcare costs compared to current procedures and devices. Currently, the company is developing a novel surgical device that will enable surgeons to use gold standard autologous bone graft material. Current bone graft solutions are suboptimal in terms of efficacy, safety, and cost. BOSS Medical aims to provide the optimal bone grafting solution in order to improve the lives of our patients worldwide.